Alterity Therapeutics Ltd Stock Australian S.E.
Stocks
AU000000PBT9
Biotechnology & Medical Research
OTC Markets Traded| Market Cap | 86.52M 75.73M 69.91M 65.21M 123M 8.18B 125M 839M 326M 4.04B 325M 318M 14.06B | P/E 2026 * |
-0.34x | P/E 2027 * | -0.33x |
|---|---|---|---|---|---|
| Enterprise Value | 41.33M 36.18M 33.4M 31.15M 58.7M 3.91B 59.75M 401M 156M 1.93B 155M 152M 6.72B | EV / Sales 2026 * |
16.1x | EV / Sales 2027 * | 38x |
| Free-Float |
91.47% | Yield 2026 * |
-
| Yield 2027 * | - |
Last Transcript: Alterity Therapeutics Ltd
| 1 day | +2.04% |
| Manager | Title | Age | Since |
|---|---|---|---|
David Stamler
CEO | Chief Executive Officer | 65 | 07/01/2021 |
Abby Niven
DFI | Director of Finance/CFO | - | 30/09/2024 |
| Chief Tech/Sci/R&D Officer | - | - |
| Director | Title | Age | Since |
|---|---|---|---|
Peter Marks
BRD | Director/Board Member | 70 | 29/07/2005 |
Lawrence Gozlan
BRD | Director/Board Member | 47 | 08/08/2011 |
David Stamler
BRD | Director/Board Member | 65 | 21/11/2025 |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | +2.04% | +2.08% | - | - | 85.31M | |
| +1.15% | +5.94% | -3.40% | +2.32% | 46.62B | |
| -2.77% | +10.48% | +409.05% | +600.11% | 40.95B | |
| -0.03% | +12.81% | +22.61% | -14.04% | 32.26B | |
| -1.73% | +3.20% | +17.72% | +59.83% | 32.24B | |
| -3.29% | +7.98% | +14.01% | +29.96% | 25.53B | |
| +1.15% | +11.79% | - | - | 16.38B | |
| -0.96% | +11.85% | +68.73% | +120.51% | 15.27B | |
| +0.56% | +5.09% | +13.43% | +17.88% | 13.61B | |
| -1.74% | +4.34% | +100.68% | +93.25% | 13.34B | |
| Average | -0.56% | +7.53% | +80.36% | +113.73% | 26.24B | |
| Weighted average by Cap. | -0.90% | +7.71% | +94.74% | +137.62% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 2.57M 2.25M 2.08M 1.94M 3.65M 243M 3.71M 24.89M 9.66M 120M 9.65M 9.43M 417M | 1.2M 1.05M 970K 905K 1.7M 113M 1.73M 11.63M 4.52M 56M 4.51M 4.41M 195M |
| Net income | -14.62M -12.8M -11.82M -11.02M -20.77M -1.38B -21.14M -142M -55.02M -682M -54.94M -53.71M -2.38B | -29.6M -25.91M -23.92M -22.31M -42.04M -2.8B -42.79M -287M -111M -1.38B -111M -109M -4.81B |
| Net Debt | -45.19M -39.55M -36.51M -34.06M -64.17M -4.27B -65.32M -438M -170M -2.11B -170M -166M -7.35B | -40.88M -35.78M -33.03M -30.81M -58.06M -3.87B -59.09M -396M -154M -1.91B -154M -150M -6.65B |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
